These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Verywell Health on MSN1d
Eli Lilly Lowers Cost of Zepbound Vials to Attract People Without Insurance Coverage
Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...
Construction Dive2d
Eli Lilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Eli Lilly's big investment, cheaper Zepbound, and Hims & Hers' options: Pharma news roundup
Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also ...
STAT5d
Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...
Eli Lilly unveils $27bn US investment as corporate America seeks to woo Trump
Eli Lilly has unveiled a $27bn investment in US manufacturing facilities as the pharmaceutical industry prepares for the threat of tariffs and mounts a charm offensive aimed at President Donald ...